📖 Read more: Seasonal Depression: Why Winter Lowers Your Mood
The Substances & The Research
The active compound in “magic mushrooms.” The study by Davis et al. (2021) in JAMA Psychiatry showed that 2 psilocybin sessions reduced depression symptoms in 71% of participants, with results lasting at least 4 weeks. Carhart-Harris et al. (2021) in the New England Journal of Medicine confirmed these findings.
The study by Mitchell et al. (2021) in Nature Medicine showed that MDMA combined with psychotherapy led to significant reduction of PTSD symptoms — 67% of participants no longer met diagnostic criteria after treatment.
📖 Read more: Social Media & Depression: What Research Shows
The only psychedelic substance already used legally (esketamine/Spravato, FDA 2019) for treatment-resistant depression. It acts in hours, not weeks like conventional antidepressants.
The Boundaries
It's critical to emphasize: psychedelics are not self-therapy. The positive results come from controlled clinical settings with preparation, guidance, and post-therapeutic processing. Unregulated use is dangerous.
📖 Read more: Cyberbullying: The Psychological Impact of Online Harassment
Psychedelic science is at a fascinating stage. It's not a panacea — but it could be a revolutionary tool for mental health.
Scientific Sources
- Davis, A. K. et al. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry, 78(5), 481–489. DOI: 10.1001/jamapsychiatry.2020.3285
- Mitchell, J. M. et al. (2021). MDMA-assisted therapy for severe PTSD. Nature Medicine, 27, 1025–1033. DOI: 10.1038/s41591-021-01336-3
- Carhart-Harris, R. et al. (2021). Trial of Psilocybin versus Escitalopram for Depression. NEJM, 384, 1402–1411. DOI: 10.1056/NEJMoa2032994